Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Link Found Between Dementia Risk and ADT for Prostate Cancer

      October 26, 2016
      By Katie Kosko
      Article

      A recent study found an increased risk of dementia for patients with prostate cancer being treated with ADT, and those patients with the highest risk had been treated with ADT for the longest period of time.

      Kevin Nead, MD

      Kevin Nead, MD

      Kevin Nead, MD

      New research suggests an increased risk of dementia in men with prostate cancer being treated with androgen deprivation therapy (ADT)—marking the first study to show a significant association between dementia and the testosterone-lowering therapy.

      The research team at Penn Medicine found a doubling of dementia risk and that the patients with the highest risk were those treated with ADT for the longest period of time.

      “Currently there is a lot of discussion about how we treat patients with prostate cancer, how we screen prostate cancer and whether we potentially give some patients more treatment then they may benefit from,” said lead author Kevin Nead, MD. “I think in that environment, the findings about side effects from that treatment are very important because they might kind of change the conversation a little bit.”

      The study, published in JAMA Oncology, included 9272 individuals with prostate cancer, and of those, 1826 men received ADT. Researchers used a text-processing method to analyze electronic medical record data from Stanford University Hospital from 1994 to 2013. The median follow-up was 3.4 years.

      Researchers found that the absolute increased risk of developing dementia was 4.4% at 5 years: 7.9% among those who received ADT versus 3.5% in those who did not.

      Individuals with at least 12 months of ADT use had the greatest absolute increased risk of dementia. There was no evidence of an interaction between use of ADT and age. The mean age of the patients was 66.9 years.

      Last year, researchers published a study that discovered an association between Alzheimer’s disease and ADT, which has been a common treatment for prostate cancer since the 1940s. However, the study reported here suggests a broader neurocognitive risk, explained Nead, a resident in the department of Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. There are ways that ADT and low testosterone can increase the risk of something like dementia.

      “Testosterone is really important for the health of neurons in the brain, and if you lower testosterone you kind of decrease the ability of the body to prevent damage or repair things when they need to be repaired,” he said.

      “ADT and low testosterone also increase cardiometabolic disease risk, and that can lead to changes in cardiovascular and vascular function, which might decrease many tissues, one of them being the brain.”

      Although the findings of this study are significant, Nead further evidence will be needed through research and controlled studies. He also reminded that ADT is still a proven effective treatment for prostate cancer.

      “I think at this point, based on very early research that is more hypothesis-generating, we need to do more research,” said Nead. “It would be really hard to justify not using a medication that we know extends life for a possible negative consequence that at this point is potential, probable at best, but not proven.”

      Nevertheless, Nead said: “This is not an academic question anymore; this is really a clinical question that needs to be answered. We have two papers here showing very similar outcomes and magnitude of risk, which I think supports the case for this to be studied prospectively.”

      Nead KT, Gaskin G, Chester C, et al. Association between androgen deprivation therapy and risk of dementia [published online October 13, 2016]. JAMA Oncol.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing glasses and a suit in front of a blue background
      Man standing in front of Oncology Nursing News-branded backdrop
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
      Related Content

      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Line illustration of the bladder and prostate on a cerulean background

      Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume

      Kyle Doherty
      February 15th 2025
      Article

      Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

      Related Content

      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Oncology Nursing News

      A Look Back at 2022 FDA Approvals in Oncology

      Oncology Nursing News
      January 2nd 2023
      Podcast

      In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      Key Advances in Cancer Survivorship Toxicity Management

      Key Advances in Cancer Survivorship Toxicity Management

      Lindsay Fischer
      July 15th 2022
      Podcast

      In this episode of The Vitals, Lidia Schapira, MD, FASCO, recounts highlights from the 2022 ASCO Symptoms and Survivorship track and underscores key takeaways for practitioners seeking to enhance the delivery of cancer survivorship care.


      Blue image of kidneys with renal tubules highlighted in red

      Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC

      Tim Cortese
      February 15th 2025
      Article

      Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.


      Line illustration of the bladder and prostate on a cerulean background

      Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume

      Kyle Doherty
      February 15th 2025
      Article

      Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.